UK Plan To Speed Access To ‘Cutting-Edge’ Products
Executive Summary
Changes are being made to the UK’s Accelerated Access Collaborative to help streamline access to ground-breaking medicines and diagnostic tools in areas like dementia, diabetes and cancer.
You may also be interested in...
Well-Intentioned, But Can The Improved AAC Work For UK Medtechs?
The newly enhanced Accelerated Access Collaborative (AAC) promises a more concerted effort to ensure health-care innovations reach end users. On paper, it looks good, but the medtech industry in the UK has seen several worthy efforts along similar lines ultimately amount to little. Health Enterprise East’s Dr. Anne Blackwood is reserving judgment.
ABPI Exec Lauds Innovation And Access Provisions In New UK Voluntary Scheme
Speakers at a meeting in London examined the key provisions of the new voluntary pricing and access scheme, which replaced the PPRS at the beginning of January. The Pink Sheet spoke to the Association of the British Pharmaceutical Industry’s Paul Catchpole about enhanced planning for the introduction of new treatments on the national health service, and the shape of the new “commercial flexibilities” intended to allow earlier patient access to innovation.
UK Medtech Industry Points The Signpost At Better Adoption of Innovation
Often seen as complicated to access, beset with high entry barriers and with no guarantee of product adoption, the UK NHS is at once a lucrative and tricky market to succeed in for medtech innovators. A new MedTech Landscape Review, from the AHSN Network, has taken on the tasks of signposting and explaining the system, its adoption pathways and its various tools and programs, in an effort to point the way for manufacturers who want to access the NHS.